| Overview |
| bsm-61921r-pe-cy3 |
| UBE2N Recombinant Monoclonal Antibody, PE-Cy3 Conjugated |
| WB |
| Human, Mouse, Rat |
| Specifications |
| PE-Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human UBE2N |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 7334 |
| P61088 |
| Cytoplasm, Nucleus |
| BLU; HEL-S-71; Ubc13; UbCH ben; UbcH13; UBCHBEN; Ube2n. |
| The UBE2V1-UBE2N and UBE2V2-UBE2N heterodimers catalyze the synthesis of non-canonical 'Lys-63'-linked polyubiquitin chains. This type of polyubiquitination does not lead to protein degradation by the proteasome. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. |
| Application Dilution |
| WB |
1:300-5000 |